FDA approvals, translated
What changed this week in FDA cancer approvals
A plain-language look at new oncology approvals, label changes, and what they do or do not mean for patients right now.
Cancer in the News
When cancer appears in headlines and culture — a public figure’s diagnosis, an awareness month, a trending study — it raises questions. We connect those moments to calm, plain-language education based on National Cancer Institute resources.
Latest
Newest first. Every post is dated, bylined and source-checked.
- ResearchFDA Approval: Revumenib (Revuforj) for Acute LeukemiaIn November 2024 the FDA approved revumenib (Revuforj), the first menin inhibitor, for relapsed or refractory acute leukemia with a KMT2A translocation.Leukemia
- ResearchNADINA Trial: Immunotherapy Before Melanoma SurgeryThe NADINA trial found two cycles of ipilimumab plus nivolumab before stage III melanoma surgery improved event-free survival over adjuvant nivolumab.Melanoma
- ResearchLAURA Trial: Osimertinib for Stage III Lung CancerThe LAURA trial led FDA to approve osimertinib after chemoradiation for unresectable stage III EGFR-mutated lung cancer. What the numbers show and don't.Lung cancer
- ResearchINTERLACE Trial: Induction Chemo in Cervical CancerThe INTERLACE trial found six weeks of induction chemotherapy before chemoradiation improved survival in locally advanced cervical cancer. The numbers.Cervical cancer
- ResearchCROWN Trial: Lorlatinib in ALK-Positive Lung CancerCROWN trial 5-year results: 60% on lorlatinib had no progression of ALK-positive advanced lung cancer at 5 years. What PFS means, plus side-effect tradeoffs.Lung cancer
- ResearchCHALLENGE Trial: Exercise After Colon Cancer ChemoThe CHALLENGE trial found a 3-year structured exercise program after colon cancer chemotherapy improved disease-free and overall survival. Key numbers.Colorectal cancer
- What Is an Individualized Neoantigen Therapy, and How Is One Made?The melanoma result in the news used a treatment built from one person's own tumor. Here is what a neoantigen is, how a personalized mRNA therapy is made, how long it takes, and why that matters for whether it can ever be routine.Melanoma
- ResearchSugary Drinks and Stomach Cancer: What the 'Nearly Triple the Risk' Study Actually FoundA study of 112,284 people found daily sugar-sweetened drinks linked to higher stomach cancer risk. The relative figure is large and the absolute risk is small. Both things are true, and the difference matters.Stomach cancer
- Recurrence-Free Survival Is Not the Same as Living LongerTrial headlines often report recurrence-free or metastasis-free survival, not overall survival. Here is what each one counts, why researchers use them, and what a result that has met one but not the other can and cannot tell you.General
- The Melanoma Vaccine Headline: What It Changes for Patients Right NowA personalized mRNA therapy improved recurrence-free survival in melanoma after surgery. What that changes today for someone who has had melanoma removed, what it does not, and what to ask at the next appointment.Melanoma
- ResearchA Personalized mRNA Cancer Vaccine Just Passed a Phase 3 Test in MelanomaMerck and Moderna say intismeran autogene plus pembrolizumab kept melanoma from coming back longer than pembrolizumab alone. What the trial measured, what it has not yet shown, and why the result is being called a first.Melanoma
- Public figureHunter Biden Says His Father's Cancer Has Spread Further: What That Phase InvolvesHunter Biden told the BBC his father's prostate cancer has moved into the bones and further, and is painful. Here is what progression, castration-resistant disease, and bone pain care actually involve.Prostate cancer
- ResearchCancer Trends in Younger Adults: Rising Rates, Falling Death Rates, and Open QuestionsSome cancer rates are rising among younger adults while death rates may move differently. The pattern varies by cancer and does not have one proven cause.Younger-adult cancer trends
- ResearchVaccines to Prevent Cancer Before It Starts: What Is Proven and What Is Being StudiedSome vaccines already prevent infections that can cause cancer. Vaccines aimed directly at precancer or inherited risk remain research tools.Cancer prevention vaccines
- ResearchThe Tumor Microenvironment: Why Cancer Research Looks Beyond Tumor CellsTumors interact with immune cells, blood vessels, connective tissue, and signals around them. That environment may affect treatment response.Tumor microenvironment
- ResearchTriple-Negative Breast Cancer Research: Why One Label Covers Different TumorsTriple-negative breast cancer lacks three common treatment targets, but other biomarkers and disease settings can still guide research and care.Triple-negative breast cancer
- ResearchSleep and Yoga Studies in Cancer Survivorship: Helpful Support, Not a Cancer TreatmentYoga and behavioral sleep programs may improve sleep or mood for some survivors. They do not treat the cancer itself.Sleep and yoga in survivorship
- ResearchRisk-Based Breast Screening: Why One Schedule May Not Fit EveryoneResearchers are studying screening schedules based on individual risk. Current decisions still depend on validated risk factors and guidance.Risk-based breast screening
- ResearchRET-Positive Lung Cancer After Surgery: How to Read Adjuvant Trial HeadlinesAdjuvant targeted therapy is given after surgery to lower recurrence risk. Trial results must be read by biomarker, stage, endpoint, and follow-up.RET-positive lung cancer
- ResearchRegulatory T Cells and Graft-versus-Host Disease: Context for a New FDA ApprovalFDA approved a donor regulatory T-cell product used with stem-cell transplantation for certain adults with blood cancers. It is not a general cancer vaccine.Regulatory T cells and stem-cell transplantation
- ResearchRare-Cancer Research: Why Shared Data and Basket Trials MatterRare cancers make large studies difficult. Networks, shared data, and biomarker-based trials can help, but small numbers require cautious conclusions.Rare cancer research
- ResearchQuality of Life in Cancer Trials: Why This Outcome Belongs Beside SurvivalCancer trials may measure symptoms, daily function, and quality of life along with tumor response and survival. Each outcome answers a different question.Quality of life in cancer research
- ResearchWhen a Public Figure Shares a Cancer Diagnosis: What Responsible Coverage Should DoA public diagnosis can raise awareness, but it does not justify guessing about stage, treatment, cause, prognosis, or private health information.Public cancer diagnoses
- ResearchPROTACs and Targeted Protein Degradation: What the Cancer Research MeansPROTACs are designed to direct unwanted proteins toward the cell's disposal system. Clinical benefit still must be demonstrated in trials.PROTAC cancer research
Our approach: no sensationalism, no speculation about anyone’s health beyond reliable public reporting, and always a bridge to trusted educational information. Educational only — not medical advice.
News vs. reference: these are timely, dated posts with a byline and sources. For evergreen how-to guides that we keep reviewed and updated over time, browse our reference library.
The news archive
Explanatory pages organized by kind of story — what happened, why it matters, and what it does not mean. Only reviewed, source-checked pages appear here.
Recurring original formats
These are the editorial lenses we use to add value beyond summarizing a headline: what changed, what the evidence can support, what it does not mean, and what to ask.
Study headline, translated
Cancer study headline, translated
A careful translation of research headlines into what was actually studied, what was found, and what still is not known.
Trial result questions
What patients should ask after this trial result
A patient-facing reading of clinical-trial news: trial phase, eligibility, endpoints, and useful questions for the care team.
Myth in the news
Cancer myth in the news: what evidence actually says
A calm evidence check for cancer claims circulating in headlines, feeds, videos, and wellness marketing.
Follow cancer news yourself
These links open live Google News searches for common cancer topics, so you can see what is being reported right now. Remember: headlines simplify — here is how to read them carefully.
💛 Support free cancer education
Cancer Explained is free for everyone. Donations help us keep creating calm, plain-language explanations based on trusted National Cancer Institute resources.